The Clearance of Midazolam and Metabolites during Continuous Renal Replacement Therapy in Critically Ill Patients with COVID-19
Authors:
Open Access
- 3 November 2023
- journal article
- research article
- Published by S. Karger AG in Blood Purification
- Vol. 53 (2) , 107-113
Abstract
Introduction: Midazolam-based continuous intravenous sedation in patients admitted to the intensive care unit (ICU) was a necessity during the COVID-19 pandemic. However, benzodiazepine-based sedation is associated with a high incidence of benzodiazepine-related delirium and additional days on mechanical ventilation. Due to the requirement of high midazolam doses in combination with the impaired renal clearance (CL) of the pharmacological active metabolite 1-OH-midazolam-glucuronide (10% compared to midazolam), ICU patients with COVID-19 and continuous renal replacement therapy (CRRT) were at risk of unintended prolonged sedation. Several CRRT-related factors may have influenced the delivered CL of midazolam and its metabolites. Therefore, the aim of the study was to identify and describe these CRRT-related factors. Methods: Pre-filter blood samples and ultrafiltrate samples were collected simultaneously. Midazolam, 1-OH-midazolam, and 1-OH-midazolam-glucuronide plasma samples were analyzed using an UPLC-MS/MS method. The prescribed CRRT dose was corrected for downtime and filter integrity using the urea ratio (urea concentration in effluent/urea concentration plasma). CL of midazolam and its metabolites were calculated with the delivered CRRT dose (corrected for downtime and saturation coefficient [SD]). Results: Three patients on continuous venovenous hemodialysis (CVVHD) and 2 patients on continuous venovenous hemodiafiltration (CVVHDF) were included. Midazolam, 1-OH-midazolam, and 1-OH-midazolam-glucuronide concentrations were 2,849 (0–6,700) μg/L, 153 (0–295) μg/L, and 27,297 (1,727–39,000) μg/L, respectively. The SD was 0.03 (0.02–0.03) for midazolam, 0.05 (0.05–0.06) for 1-OH-midazolam, and 0.33 (0.23–0.43) for 1-OH-midazolam-glucuronide. The delivered CRRT CL was 1.4 (0–1.7) mL/min for midazolam, 2.7 (0–3.5) mL/min for 1-OH-midazolam, and 15.7 (4.0–27.7) mL/min for 1-OH-midazolam-glucuronide. Conclusions: Midazolam and 1-OH-midazolam were not removed during CVVHD and CVVHDF. However, 1-OH-midazolam-glucuronide was removed reasonably, approximately up to 43%. CRRT modality, filter integrity, and downtime affect this removal. These data imply a personalized titration of midazolam in critically ill patients with renal failure and awareness for the additional sedative effects of its active metabolites.Keywords
This publication has 22 references indexed in Scilit:
- A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokineticsCritical Care, 2015
- Effluent Volume in Continuous Renal Replacement Therapy Overestimates the Delivered Dose of DialysisClinical Journal of the American Society of Nephrology, 2011
- Principles of antibacterial dosing in continuous renal replacement therapyCritical Care Medicine, 2009
- Clinical Pharmacokinetic Monitoring of Midazolam in Critically Ill PatientsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2007
- Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltrationAmerican Journal of Kidney Diseases, 2005
- Midazolam Disposition in Patients Undergoing Continuous Venovenous HemodialysisThe Journal of Clinical Pharmacology, 2001
- Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow ratesAmerican Journal of Kidney Diseases, 1999
- Pharmacokinetics of continuous renal replacement therapyIntensive Care Medicine, 1995
- Prolonged sedation due to accumulation of conjugated metabolites of midazolamThe Lancet, 1995
- Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteersClinical Pharmacology & Therapeutics, 1992